Y. Fujita

发表

Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer

K. Matsumoto, M. D. De Velasco, K. Nishio, 2011, British Journal of Cancer.

Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition

N. Saijo, Kaoru Tanaka, K. Nishio, 2010, Cancer science.

PDZK1 induces resistance to apoptosis in esophageal adenocarcinoma cells

H. Matsumoto, K. Nishio, O. Handa, 2021, Esophagus.

Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer

S. Tomida, M. D. De Velasco, K. Nishio, 2015, SpringerPlus.

Single nucleotide polymorphism markers for low‐dose aspirin‐associated peptic ulcer and ulcer bleeding

K. Haruma, K. Nishio, Y. Fujimura, 2014, Journal of gastroenterology and hepatology.

Erythropoietin contributes to implantation: Ectopic hemoglobin synthesis in decidual cells of mice

M. Maeda, H. Fujita, T. Atsumi, 2007, Congenital anomalies.

Death-resistant and nonresistant malignant human cell lines under anoxia in vitro

H. Utsumi, S. Koinuma, S. Taketani, 2007, International Journal of Clinical Oncology.

De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer

M. Fukuoka, K. Nishio, I. Okamoto, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Collateral Chemoresistance to Anti-Microtubule Agents in a Lung Cancer Cell Line with Acquired Resistance to Erlotinib

Y. Maehara, T. Mitsudomi, S. Tomida, 2015, PloS one.

An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer.

T. Mitsudomi, S. Tomida, M. D. De Velasco, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular endothelial cells.

K. Nishio, K. Furuta, K. Sakai, 2011, Anticancer research.

Melanoma Transition Is Frequently Accompanied by a Loss of Cytoglobin Expression in Melanocytes: A Novel Expression Site of Cytoglobin

M. D. De Velasco, K. Nishio, S. Koinuma, 2014, PloS one.

Novel Single Nucleotide Polymorphism Markers for Low Dose Aspirin-Associated Small Bowel Bleeding

K. Haruma, K. Nishio, Y. Fujimura, 2013, PloS one.

Vascular endothelial growth factor in edematous mouse embryos induced by retinoic acid in utero

Y. Fujita, Y. Yasuda, H. Konishi, 2001 .

mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells.

N. Saijo, Kaoru Tanaka, K. Nishio, 2009, Cancer research.

Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors

K. Nishio, T. Okawara, R. Islam, 2012, Investigational New Drugs.

The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer

K. Matsumoto, K. Nishio, I. Okamoto, 2013, Oncogene.

Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients.

T. Yamanaka, K. Nishio, Y. Tanigawara, 2012, Oncology reports.

Expression of erythropoietin in human female reproductive organs.

Y. Nakamura, Y. Fujita, S. Shiokawa, 2001, Italian journal of anatomy and embryology = Archivio italiano di anatomia ed embriologia.

KIAA1199 interacts with glycogen phosphorylase kinase β-subunit (PHKB) to promote glycogen breakdown and cancer cell survival

S. Tomida, M. D. De Velasco, K. Nishio, 2014, Oncotarget.

Incidence of carnitine deficiency in patients with cancer pain: A pilot study

K. Nishio, H. Matsuoka, Masatomo Otsuka, 2017, Molecular and clinical oncology.

SRPX2 Is a Novel Chondroitin Sulfate Proteoglycan That Is Overexpressed in Gastrointestinal Cancer

Kaoru Tanaka, K. Nishio, K. Yanagihara, 2012, PloS one.

SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion

Kaoru Tanaka, H. Yokote, K. Nishio, 2009, International journal of cancer.

Characterization of the cytotoxic activity of [2]rotaxane (TRO-A0001), a novel supramolecular compound, in cancer cells

Hiroki Sato, K. Nishio, T. Takata, 2016, Archives of Pharmacal Research.

Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer.

Masato Terashima, Masatoshi Kudo, Masayuki Kitano, 2015, Cancer letters.

Erythropoietin and erythropoietin-receptor producing cells demonstrated by in situ hybridization in mouse visceral yolk sacs

S. Masuda, M. Nagao, R. Sasaki, 2002, Anatomical science international.

Early effects of boron neutron capture therapy on rat glioma models

K. Ono, Minoru Suzuki, M. Taneda, 2007, Brain Tumor Pathology.

Influence of novel supramolecular substance, [2] rotaxane, on the caspase signaling pathway in melanoma and colon cancer cells in vitro.

K. Nishio, T. Takata, Y. Fujita, 2013, Journal of pharmacological sciences.

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing

Masato Terashima, Shuta Tomida, Kazuko Sakai, 2015, PloS one.

N‐Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor

C. Shimizu, Y. Fujiwara, Kaoru Tanaka, 2008, Cancer science.

Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice

S. Masuda, M. Nagao, R. Sasaki, 2001, British Journal of Cancer.

Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma

M. Kudo, N. Saijo, K. Nishio, 2011, Molecular Cancer Therapeutics.

FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth.

Kaoru Tanaka, M. D. De Velasco, K. Nishio, 2010, Cancer research.

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Yusuke Nakamura, T. Mitsudomi, M. D. De Velasco, 2017, BMC Cancer.

MEK inhibitors against MET-amplified non-small cell lung cancer

Yusuke Nakamura, T. Mitsudomi, S. Tomida, 2016, International journal of oncology.

Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2

Yusuke Nakamura, T. Mitsudomi, S. Tomida, 2016, Clinical Cancer Research.

Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.

S. Tomida, K. Nishio, Y. Iwamoto, 2020, JAMA oncology.

Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.

H. Mukai, Y. Ohashi, K. Nishio, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 5169: Novel target molecules for treatment of cancer of unknown primary

K. Nishio, K. Nakagawa, T. Kurata, 2018, Tumor Biology.

Abstract 3993: A microarray-based gene expression analysis identified diagnostic biomarkers for unknown primary cancer

K. Nishio, Y. Koh, K. Nakagawa, 2014 .

Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.

S. Tomida, M. D. De Velasco, K. Nishio, 2015, Lung cancer.

O3-15-2CHRONIC NICOTINE EXPOSURE MEDIATES RESISTANCE TO EGFR-TKI IN EGFR-MUTATED LUNG CANCER VIA EGFR SIGNAL

S. Tomida, K. Nishio, K. Okamoto, 2014 .

Erythropoietin regulates tumour growth of human malignancies.

Yoshiko Yasuda, Kazuhiro Ogawa, Yukio Nakamura, 2003, Carcinogenesis.

Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs.

S. Masuda, M. Nagao, R. Sasaki, 2002, Carcinogenesis.

Clinicopathological and genetic differences between low‐grade and high‐grade colorectal mucinous adenocarcinomas

K. Okuno, S. Tomida, M. D. De Velasco, 2015, Cancer.

A Microarray-Based Gene Expression Analysis to Identify Diagnostic Biomarkers for Unknown Primary Cancer

Yuichi Takiguchi, Hirofumi Mukai, Nobuyuki Yamamoto, 2013, PloS one.

A Novel Mass Spectrometry–Based Assay for Diagnosis of EML4-ALK–Positive Non–Small Cell Lung Cancer

K. Nishio, I. Okamoto, K. Takezawa, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production

M. D. De Velasco, K. Nishio, H. Shiozaki, 2013, Oncotarget.

Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation

Y. Yatabe, T. Mitsudomi, N. Saijo, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical and immune profiling for cancer of unknown primary site

S. Tomida, K. Nishio, J. Tanizaki, 2019, Journal of Immunotherapy for Cancer.

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib

Yusuke Nakamura, T. Mitsudomi, M. D. De Velasco, 2016, Cancer science.

aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.

T. Yamanaka, E. Baba, N. Sugimoto, 2018, The oncologist.

Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.

K. Okuno, S. Tomida, M. D. De Velasco, 2015, International journal of oncology.

Molecular biomarker identification for esophageal adenocarcinoma using endoscopic brushing and magnified endoscopy

M. Wallace, H. Wolfsen, H. Matsumoto, 2020, Esophagus.

TGF-β induces sustained upregulation of SNAI1 and SNAI2 through Smad and non-Smad pathways in a human corneal epithelial cell line.

Koji Sugioka, Yoshikazu Shimomura, Daisuke Tamura, 2011, Investigative ophthalmology & visual science.

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?

Yusuke Nakamura, T. Mitsudomi, M. D. De Velasco, 2016, Cancer science.

Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition

K. Okuno, S. Tomida, M. D. De Velasco, 2014, International journal of oncology.

Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition

K. Okuno, S. Tomida, M. D. De Velasco, 2014, International Journal of Oncology.

Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor

K. Nishio, M. Nishio, K. Sakai, 2013, Cancer science.

An early event of EGFR mutation in pleomorphic carcinoma of the lung

K. Nishio, K. Hiroshima, K. Tatsumi, 2011, International Journal of Clinical Oncology.

Inhibition of &bgr;-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation

S. Tomida, M. D. De Velasco, K. Nishio, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Significance of FGF9 gene in resistance to anti‐EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti‐EGFR therapies

S. Tomida, M. D. De Velasco, K. Nishio, 2017, Molecular carcinogenesis.

Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non‐small cell lung cancer

M. Fukuoka, K. Nishio, I. Okamoto, 2008, Cancer science.

EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.

S. Tomida, M. D. De Velasco, K. Nishio, 2015, International journal of oncology.

Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC

Yusuke Nakamura, S. Tomida, M. D. De Velasco, 2016, Molecular Cancer Therapeutics.

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma

K. Okuno, K. Nishio, H. Shiozaki, 2013, International journal of oncology.

Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib.

Yusuke Nakamura, M. Kudo, M. D. De Velasco, 2017, International journal of oncology.

Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer

M. Kudo, S. Tomida, M. D. De Velasco, 2014, Molecular Cancer.

Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients.

T. Yamanaka, K. Nishio, H. Matsuoka, 2011, Anticancer research.

MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations

K. Okuno, S. Tomida, M. D. De Velasco, 2014, Molecular Cancer Therapeutics.

Cancer Biology and Signal Transduction MEK Inhibitor for Gastric Cancer with MEK 1 Gene Mutations

K. Okuno, S. Tomida, K. Nishio, 2014 .

Overexpression of heparan sulfate 6-O-sulfotransferase-2 in colorectal cancer

K. Okuno, M. D. De Velasco, K. Nishio, 2013, Molecular and clinical oncology.

Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study)

K. Nishio, H. Matsuoka, Y. Otake, 2017, BMC Cancer.

Impact of Tight Junction Protein ZO-1 and TWIST Expression on Postoperative Survival of Patients with Hepatocellular Carcinoma

M. Kudo, Y. Minami, S. Hagiwara, 2016, Digestive Diseases.

Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells

W. Nishio, C. Ohbayashi, M. D. De Velasco, 2013, Cancer medicine.

Slug Is Upregulated during Wound Healing and Regulates Cellular Phenotypes in Corneal Epithelial Cells Methods Wound Healing Model in Animal Study Biochemistry and Molecular Biology

K. Sugioka, K. Nishio, Y. Shimomura, 2022 .

Integrated analysis of whole genome exon array and array‐comparative genomic hybridization in gastric and colorectal cancer cells

K. Nishio, K. Yanagihara, M. Sekijima, 2012, Cancer science.

EGFR mutation up-regulates EGR1 expression through the ERK pathway.

Kaoru Tanaka, H. Yokote, K. Nishio, 2009, Anticancer research.

Overexpression of CD55 from Barrett's esophagus is associated with esophageal adenocarcinoma risk

K. Haruma, J. Hata, K. Nishio, 2016, Journal of gastroenterology and hepatology.

Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study)

Kaoru Tanaka, K. Nishio, H. Matsuoka, 2022, The oncologist.

Prospective replication study implicates the catechol-O-methyltransferase Val158Met polymorphism as a biomarker for the response to morphine in patients with cancer.

K. Nishio, H. Matsuoka, K. Sakai, 2017, Biomedical reports.

Expectation of a Decrease in Pain Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of Response to Morphine

K. Nishio, H. Matsuoka, K. Sakai, 2017, International Journal of Behavioral Medicine.

Epidermal growth factor receptor lacking C‐terminal autophosphorylation sites retains signal transduction and high sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor

Kaoru Tanaka, H. Yokote, K. Nishio, 2009, Cancer science.

Slug Increases Sensitivity To Tubulin Binding Agents Via The Downregulation Of Beta III And IVa-Tubulin In Lung Cancer Cells

W. Nishio, N. Saijo, K. Nishio, 2012, ATS 2012.

Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo

M. Kudo, N. Saijo, Kaoru Tanaka, 2010, Clinical Cancer Research.

Characterization of the cytotoxic activity of [2]rotaxane (TRO-A0001), a novel supramolecular compound, in cancer cells

K. Nishio, T. Takata, Y. Fujita, 2016, Archives of pharmacal research.

2169 Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinoma

K. Okuno, S. Tomida, K. Nishio, 2015 .

Low-Dose Aspirin-Associated Upper and Mid Gastrointestinal Tract Damage and Gene Polymorphism.

K. Nishio, A. Shiotani, Y. Fujita, 2015, Current pharmaceutical design.

Abstract. Patients with non-small cell lung cancer (NSCLC) with echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangements

K. Okuno, S. Tomida, K. Nishio, 2014 .

Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.

S. Tomida, M. D. De Velasco, K. Nishio, 2015, Lung cancer.

Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production

M. D. De Velasco, K. Nishio, H. Shiozaki, 2013, Oncotarget.

Single nucleotide polymorphism markers for low‐dose aspirin‐associated peptic ulcer and ulcer bleeding

K. Haruma, Y. Fujimura, A. Shiotani, 2014, Journal of gastroenterology and hepatology.

Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma

M. Kudo, N. Saijo, K. Nishio, 2011, Molecular Cancer Therapeutics.

721 Novel Single Nucleotide Polymorphism Markers for Low Dose Aspirin-Associated Small Bowel Bleeding: A DMET Microarray Profiling Study

K. Haruma, K. Nishio, Y. Fujimura, 2014 .

Slug is upregulated during wound healing and regulates cellular phenotypes in corneal epithelial cells.

T. Arao, H. Hayashi, K. Aomatsu, 2012, Investigative ophthalmology & visual science.